Prognostic significance of TEL/AML1 fusion transcript in childhood B- precursor acute lymphoblastic leukemia

Yoshiyuki Takahashi, Keizo Horibe, Hitoshi Kiyoi, Yoshiko Miyashita, Minoru Fukuda, Hiroshi Mori, Chika Nozaki, Shinji Hasegawa, Takashi Kawabe, Koji Kato, Seiji Kojima, Takaharu Matuyama, Tomoki Naoe

研究成果: Contribution to journalArticle査読

57 被引用数 (Scopus)


Purpose: A retrospective study was conducted to investigate the prognostic significance of TEL/AML1 fusion resulting from a cryptic t(12;21) in Japanese patients with childhood B-precursor acute lymphoblastic leukemia (ALL). Materials and Methods: Leukemic samples from 144 children with newly diagnosed ALL (104 with CD10-positive B-precursor ALL, 11 with CD10-negative B-precursor ALL, 5 with BALL, and 24 with T-ALL) were analyzed by reverse- transcription polymerase chain reaction. Results: The frequency of patients with TEL/AML1 was 16% (23 of 144) and all patients with TEL/AML1 also had CD10-positive B-precursor ALL. TEL/AML1 was not found in any samples from the patients with T-ALL, B-ALL, or CD10-negative B-precursor ALL. Among patients with CD10-positive B-precursor ALL, age, initial white blood cell count, and immunophenotype did not differ with TEL/AML1 positivity, although the patients were predominantly male (p < 0.01). Clinical outcomes of 94 patients treated with recent protocols were analyzed. Five of the 21 (23.8%) patients with TEL/AML1 relapsed and 4 of these relapsed > 24 months after diagnosis. Although the overall 5-year survival rate was better among patients with TEL/AML1 fusion transcript than among those without it (87.3 ± 8.7% versus 75.9 ± 5.8%, respectively), the 5-year disease-free survival (DFS) rates of patients with TEL/AML1 fusion transcript and those without it were similar (64.0 ± 13.5% versus 69.1 ± 6.3%, respectively). However, for 57 patients treated with the latest intensive protocol, the 4-year DFS rate was much higher for the patients with TEL/AML1 fusion transcript than for those without it (100.0% v.s. 69.6 ± 8.4%, respectively, p = 0.1472). Conclusions: This study confirmed that TEL/AML1 gene fusion is the most common genetic event in pediatric ALL in Japan and is restricted to CD10-positive B- precursor ALL. Moreover, it was associated with an improved survival rate among patients treated with intensive therapy. Therefore, these data suggest that the patients with TEL/AML1 may not necessarily be candidates for less aggressive treatment.

ジャーナルJournal of Pediatric Hematology/Oncology
出版ステータス出版済み - 5 1998

All Science Journal Classification (ASJC) codes

  • 小児科学、周産期医学および子どもの健康
  • 血液学
  • 腫瘍学


「Prognostic significance of TEL/AML1 fusion transcript in childhood B- precursor acute lymphoblastic leukemia」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。